TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01799889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib MM
Description: Entospletinib MM tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib MM
Description: Entospletinib MM tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib MM
Description: Entospletinib MM tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib MM
Description: Entospletinib MM tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib MM
Description: Entospletinib MM tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib SDD
Description: Entospletinib SDD tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib SDD
Description: Entospletinib SDD tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib SDD
Description: Entospletinib SDD tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib SDD
Description: Entospletinib SDD tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib SDD
Description: Entospletinib SDD tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib SDD
Description: Entospletinib SDD tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib SDD
Description: Entospletinib SDD tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib SDD
Description: Entospletinib SDD tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib SDD
Description: Entospletinib SDD tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib SDD
Description: Entospletinib SDD tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib SDD
Description: Entospletinib SDD tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib SDD
Description: Entospletinib SDD tablet administered orally
Study: NCT02593500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonida Pulmictan® 200 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonida Pulmictan® 200 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 200 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 200 µg
Study: NCT04415801

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Repeated removal and re-placement of healing and prosthetic abutments
Description: Repeated removal and re-placement of healing and prosthetic abutments
Study: NCT01147822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg administered once daily orally continuous dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg sunitinib to be administered in 6-week cycle: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
Study: NCT03928366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: remifentanil
Study: NCT02598453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Either 150 mg oral tablet once monthly or 3 mg IV injection once every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Either 150 mg oral tablet once monthly or 3 mg IV injection once every 3 months
Study: NCT00547144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenoulsy once a week according to protocol schedule

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Immunotherapy
Description: The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart)
Study: NCT03938571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal Switch

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenal Switch
Study: NCT01042795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg daily X 16 weeks
Study: NCT01586195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib 960 mg BID
Study: NCT00320047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Participants will take baclofen 3 times a day, before meals, for 10 weeks. Baclofen dosages will be low to begin, followed by a gradual increase over a 2-week period. Upon reaching the maximum tolerated dose of baclofen, participants will continue at this dosage level until Week 11, at which time the dose will be gradually decreased. If any serious side effects occur, baclofen dosage will be decreased to the previous tolerated dosage level.
Study: NCT00296244

Intervention type: DRUG
Group type: OTHER
Intervention: Steroids
Description: Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.

Intervention type: DRUG
Group type: OTHER
Intervention: Basiliximab
Description: Basiliximab shall be given as induction therapy at 20 mg IV bolus intra-operatively and on the 4th day after transplantation.

Intervention type: DRUG
Group type: OTHER
Intervention: Basiliximab
Description: Basiliximab shall be given as induction therapy at 20 mg IV bolus intra-operatively and on the 4th day after transplantation.

Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Tacrolimus shall be used as the main maintenance immuno-suppressive drug. It will be given at a dose of 0.15mg/ kg/ day by mouth or through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of 10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml, thereafter.

Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Tacrolimus shall be used as the main maintenance immuno-suppressive drug. It will be given at a dose of 0.15mg/ kg/ day by mouth or through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of 10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml, thereafter.

Intervention type: DRUG
Group type: OTHER
Intervention: Enteric-coated Mycophenolic acid (EC-MPA)
Description: This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Enteric-coated Mycophenolic acid (EC-MPA)
Description: This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.
Study: NCT03356717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention with observer tool
Description: To assess if the use of an observer tool by observers during high fidelity simulation improves learning outcomes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: without observer tool
Study: NCT02420639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.
Description: Use of the Esophageal Cooling Device for control of patient temperature.
Study: NCT02899520

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference method
Description: Electrostimulation associated to perineal training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CMP ® method
Description: Method based on Knowledge and Control of Perineum
Study: NCT01077557

Intervention type: OTHER
Intervention: No Antiretroviral (ARV) Drug Exposure
Description: No pharmacy dispensing of an ARV drug

Intervention type: OTHER
Intervention: No Antiretroviral (ARV) Drug Exposure
Description: No pharmacy dispensing of an ARV drug

Intervention type: DRUG
Intervention: Any Antiretroviral (ARV) Drug Exposure
Description: Pharmacy dispensing claim for any ARV drug
Study: NCT02957201

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples at baseline and 3 timepoints for EPC analysis
Study: NCT01781897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: sterile, disposable needles with a length of 40 mm and a diameter of 0.25 mm (Dongbang® Acupuncture Inc, Korea)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: sterile, disposable needles with a length of 40 mm and a diameter of 0.25 mm (Dongbang® Acupuncture Inc, Korea)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mosapride
Description: Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: mosapride
Description: Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan
Study: NCT01182025

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western therapy
Description: Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiyanping Injection
Description: Dosage for child medication:~5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiyanping Injection with western medicine
Description: 1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Symptomatic treatment using the same treatment methods in Xiyanpin injection group.
Study: NCT01803438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoballoon ablation system

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic Drugs
Description: AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
Study: NCT01294423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for Dapagliflozin 5mg/10mg oral dose
Study: NCT04933318

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneus electrical nerve stimulation (TENS)- analgesic current therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: shamTENS
Description: shamTranscutaneus electrical nerve stimulation (shamTENS)- analgesic current therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IFC
Description: Interferential current therapy (IFC)- analgesic current therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: shamIFC
Description: shamInterferential current therapy (shamIFC)- analgesic current therapy
Study: NCT00641056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Once Weekly
Description: subcutaneous injection, 2.0mcg, once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: subcutaneous injection, variable dose, QD
Study: NCT00301834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Study: NCT01238900

Intervention type: PROCEDURE
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Description: Endoscopic Retrograde Cholangiopancreatography (ERCP) with placement of metal stent in the bile duct
Study: NCT01034176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin
Description: 500 mg tablet, daily, 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no dose, tablet, daily, 30 days
Study: NCT01451892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance Therapy
Description: overweight individuals participating in a patient education program for obese people combined with specific dance-therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient education
Description: overweight individuals participating in a patient education program
Study: NCT03559231

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dFTRD
Description: Duodenal Full-Thickness Resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMR
Description: Endoscopic Mucosal Resection
Study: NCT00301834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Study: NCT03884010

Intervention type: OTHER
Intervention: No intervention
Description: Cross-sectional
Study: NCT02517749

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chest Drain Insertion and Talc Pleurodesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling Pleural Catheter Insertion and Talc Pleurodesis
Study: NCT04887363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core exercise
Description: Participants will receive12-week, 60 minutes, 36-session exercise-based core stability training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: Participants will receive 12-week, 60 minutes, 36-session Tai Chi exercise training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.
Study: NCT01099644

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 131 I-8H9
Description: Patients will be administered therapeutic dose of IP 131I-8H9 per the dose escalation regimen. 131I-8H9 pharmacokinetics will be studied by serial blood draws from indwelling venous lines. 131I-8H9 biodistribution will be studied by a single gamma camera scan about 5 days after IP injection where feasible.
Study: NCT04578366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description: ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
Study: NCT03740464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: long-acting granulocyte colony stimulating factor
Description: A 6 mg of polyethylene glycol granulocyte colony stimulating factor will be given to patients of study group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-term granulocyte colony stimulating factor
Description: Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-term granulocyte colony stimulating factor
Description: Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression
Study: NCT04306523

Intervention type: OTHER
Intervention: Observation
Description: 4 months: observation of infant feeding behavior, behavior/temperament; bio-specimen collection; body composition, sucking intensity/frequency, activity intensity/frequency; maternal reports of feeding and behavior/temperament; maternal biospecimen. 6 month: behavior/temperament assessment, physical activity, and body composition. 12 month: Feeding behavior, behavior/temperament assessment, physical activity, and body composition. 24 month: maternal reports of children's eating behavior, behavior/temperament.
Study: NCT03821961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metabolic Surgery
Description: Roux-en-Y gastric bypass, Sleeve gastrectomy
Study: NCT02254746

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Study: NCT01469871

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing of wound
Description: The wound will be dressed using the Hypafix Transparent dressing after hip surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing of wound
Description: The wound will be dressed using the Mepore Pro dressing after hip surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing of wound
Description: The wound will be dressed using the Mepilex Border dressing after hip surgery.
Study: NCT02144909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partners in Care with Semi-Structured Support Group
Study: NCT00744939

Intervention type: DRUG
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Description: Patients will be followed for 2 years after the administration of Magnevist at the approved dose to see if symptoms consistent with NSF develop
Study: NCT02744716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: low dose of Aspirin after operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: low dose of Aspirin after operation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrauterine balloon
Description: insert intrauterine balloon after operation
Study: NCT04820907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1904-1
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2001-1
Description: Take it once daily for 8 weeks orally.
Study: NCT01739335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone Oral Tablet [Korlym]
Description: 2 Mifepristone 300 MG Oral Tablets once daily (600mg total) for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 2 Placebo Oral Tablets once daily for 7 days
Study: NCT02613130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrate toothpaste
Study: NCT01130844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX Mesalamine
Description: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX Mesalamine
Description: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX Mesalamine
Description: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
Study: NCT02704754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: First in class orexin antagonist recently approved by the FDA for the treatment of insomnia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pill with inactive ingredients
Study: NCT01386762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 6 months of intense multi-modal exercise consisting of vibration exercise, gait training, electrical stimulation, etc.
Study: NCT02002663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2%
Description: PCA morphine 0.5 mg/ml bolus 1 mg LO 5 min max 20 mg in 4 hs
Study: NCT04171323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will be completing a total of 40 computerized sessions.
Study: NCT02002663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 1mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9%
Study: NCT04168242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp cooling Paxman Orbis II system
Description: The experimental arm will have scalp cooling that starts 30 minutes before the chemotherapy, continues throughout the infusion of the chemotherapy, and lasts for 20-90 minutes more depending on the type of regimen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: The control arm will not have scalp cooling before, during and after chemotherapy.